There is some exciting news from the Medicines Patent Pool in that Mylan have signed on to produce a generic glecaprevir/pibrentasvir.
This is really significant for areas of Africa where the subtypes of HCV are very resistant to DAAs, for patient with renal failure and for patients who have failed one or more DAA treatments.
It should make obtaining the combination of glecaprevir, pibrentasvir and sofosbuvir affordable for the first time ever.
Given these 3 drugs are the strongest NS3/4A, NS5A and NS5B inhibitors in existance this offers real hope to patients with difficult resistance and is as close to “Perfectovir” as we are ever likely to get…
